The Link Between Psoriasis and Liver Diseases

Introduction

A chronic inflammatory skin disorder that affects millions worldwide, psoriasis has lately been linked with numerous systemic disorders, including the liver. Various studies conducted throughout the past few decades point to significant connections between psoriasis and liver disorders. Psoriasis patients are more prone to liver disorders, and systemic drugs like Methotrexate may lead to liver toxicity. Obesity, metabolic syndrome, and hereditary risks are common risk factors that are common to both liver disorders and psoriasis. Routine monitoring of liver function is necessary to identify any liver problems early on during psoriasis treatment. Patients with psoriasis should be cautious with drugs like Acitretin, Cyclosporine, and Methotrexate because they can induce liver problems. This article elaborates on whether psoriasis is a sign of liver problems.

What Is the Pathological Link Between Psoriasis and Liver Disease?

Medical research has increasingly recognized the link between psoriasis and liver diseases:

• Inflammatory Pathways: Chronic inflammation occurs in both psoriasis and liver diseases. Psoriasis causes rapid skin cell turnover and inflammation due to an overactive immune response. Similarly, liver diseases like non-alcoholic fatty liver disease and non-alcoholic steatohepatitis involve inflammation of liver tissues. Key inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-17 (IL-17), play crucial roles in both conditions.

• Metabolic Syndrome: A group of conditions called metabolic syndrome, obesity, hypertension, dyslipidemia, and insulin resistance are frequently seen in patients with psoriasis. Psoriasis is one of the risk factors for NAFLD (non-alcoholic fatty liver disease) and NASH (nonalcoholic steatohepatitis). Metabolic syndrome in the affected patients intensifies the inflammation and fat accumulation in the liver, resulting in the worsening of liver disease.

• Insulin Resistance: Insulin resistance is common in psoriasis and liver diseases. It leads to increased fat deposition in the liver and causes complications of psoriasis, which can progress to NAFLD and NASH. Psoriasis patients often exhibit higher levels of insulin resistance, linking the skin condition to liver health.

• Oxidative Stress: Oxidative stress is another common factor that causes an imbalance between free radicals and antioxidants in the body. It can directly cause skin inflammation and damage. Likewise, in liver diseases, this oxidative stress can result in liver cell damage due to inflammation and fibrosis.

What Types of Liver Problems Are Common in Patients With Psoriasis?

• Non-Alcoholic Fatty Liver Disease (NAFLD): Studies have consistently shown a higher prevalence of NAFLD in individuals with psoriasis compared to the general population. NAFLD refers to a spectrum of liver conditions identified by excessive fat deposition in the liver, not caused by alcohol consumption. Shared inflammatory pathways and insulin resistance are thought to underlie the link between psoriasis and NAFLD. Chronic inflammation in psoriasis may contribute to liver inflammation and fat accumulation, exacerbating liver disease progression.

• Non-Alcoholic Steatohepatitis (NASH): NASH refers to an intense type of NAFLD, that causes liver inflammation and potentially progresses to fibrosis and cirrhosis. Psoriasis patients are at increased risk of NASH compared to the general population. Similar mechanisms involving insulin resistance, oxidative stress, and inflammatory cytokines contribute to the development of NASH in psoriasis patients.

• Hepatitis B and C: Psoriasis patients receiving systemic treatments, particularly biologic therapies suppressing the immune system, may be at increased risk of reactivating hepatitis B or worsening hepatitis C infection. Screening for hepatitis B and C before initiating immunosuppressive therapy in psoriasis patients is crucial to prevent complications.

What Are the Clinical Characteristics of Liver Problems in Patients with Psoriasis?

• Liver disease in psoriasis patients can vary from simple steatosis (NAFLD) and nonalcoholic steatohepatitis (NASH) to fibrosis and cirrhosis.

• Typically, it is asymptomatic and often detected incidentally through blood tests or during the planning of systemic treatment.

• In rare cases, psoriasis of the liver manifests as an enlarged liver that can be palpable during an examination. In advanced stages, visible skin signs may indicate liver failure.

What Complications Can Arise From Liver Problems in Patients With Psoriasis?

• Liver disease can increase from being asymptomatic to developing into hepatocellular carcinoma, hepatocellular carcinoma, and liver cirrhosis.

• Immunosuppressive systemic methods to treat psoriasis related to liver disease can reactivate viral hepatitis; therefore, screening is crucial before starting these therapies.

Signs of Liver Issues in Psoriasis Patients:

A disease known as NAFLD results from the accumulation of an excessive amount of fat in liver cells. This disease may eventually lead to cirrhosis and liver failure.

Even though NAFLD currently affects approximately 30 percent of the population, some studies show that up to 50 percent of people with psoriasis have NAFLD. This could be for two main reasons:

Other diseases that increase the chances of developing non-alcoholic fatty liver disease include:

• Obesity.

• Type 2 diabetes.

• High blood pressure.

• Raised cholesterol.

All of which are common in people suffering from psoriasis.

What Methods Are Used to Diagnose Liver Disease?

Liver disease is initially diagnosed through blood tests that show mild elevations in liver enzymes such as aspartate transaminase (AST), alanine transaminase (ALT), and gamma-glutamyl transferase (GGT). Other changes may include low albumin and high bilirubin levels. Non-alcoholic fatty liver disease (NAFLD) refers to an AST/ALT ratio of less than one, whereas in alcoholic liver disease, this ratio is more significant than two. Blood tests should also screen for hepatitis B and C infections.

The Fatty Liver Index (FLI) tool evaluates four parameters:

• Waist circumference.

• Serum triglycerides.

• Body mass index (BMI).

• Gamma-glutamyl transferase (GGT).

The need for liver biopsy is reduced due to imaging techniques, such as ultrasound and transient elastography, as they are used to assess the liver condition better.

Liver Conditions That Increase Your Risk of Psoriasis:

However, there is a mutual association, as psoriasis is also a risk factor for liver disease. Some other types of liver disease also heighten psoriasis risk, according to some studies. This includes:

• Alcohol-related liver disease.

• An autoimmune condition called primary biliary cholangitis causes your body to destroy your liver's bile ducts.

• An uncommon condition called autoimmune hepatitis causes your body to target your liver cells.

• Hepatitis C.

Whether psoriasis and liver disease are more or less common in people of color is unknown. Although psoriasis is more common in white people than in Black or Hispanic people, it might just be that fewer people in those groups receive a diagnosis. Many often, persons with psoriasis are misdiagnosed or go undetected.

How Is Liver Disease Treated in Patients With Psoriasis?

1. General Approaches:

Lifestyle changes to reduce the risk of or prevent the progression of NAFLD include:

• Losing weight.

• Taking vitamin D supplements if there is a deficiency.

• Decreasing the intake of saturated fats and sugar in the diet.

• Drinking coffee.

• Exercising regularly.

• Minimizing alcohol consumption.

2. Systemic Approaches:

Systemic treatments for psoriasis, such as Methotrexate, Ciclosporin, and Acitretin, can affect the liver or lipid levels and should be avoided or minimized with careful monitoring in patients with liver disease. High doses of Ciclosporin and Acitretin are particularly risky in obese patients, increasing the likelihood of adverse effects. Apremilast may be a suitable alternative. Biologic agents used for psoriasis and liver damage have varying effects on the liver. Etanercept has been reported to improve insulin sensitivity, reduce the AST/ALT ratio, and lower the risk of hepatic fibrosis. Adalimumab and Ustekinumab are considered safe for patients with liver disease. However, infliximab may cause liver problems and should be used with caution in patients with liver failure.

3. Specific Approaches:

Hepatitis C infection is now a curable disease. Managing psoriasis-associated conditions such as hypertension, type II diabetes mellitus, and hyperlipidemia reduces the risk of further complications from metabolic syndrome. NAFLD is projected to become the primary reason for liver transplantation globally.

What Is the Prognosis for Liver Problems in Patients with Psoriasis?

A significant study in the UK found that 14.1 percent of patients with severe psoriasis had advanced liver fibrosis, representing a seven-fold increase compared to the general population.

Studies show that psoriasis is associated with co-morbid conditions like diabetes, obesity, and insulin resistance. Hence, the existence of such ailments influences the prognosis of liver problems. Also, the long-term survival rate is greatly reduced in hepatic problems such as liver cirrhosis and hepatocellular carcinoma.

Conclusion

A comprehensive assessment of factors linking liver problems and psoriasis is essential for a better understanding of the disease progression. Detailed facts help to tailor personalized patient care and formulate precise treatment interventions. Scientific studies focus on identifying interconnecting pathways and potential risk determinants for developing liver complications in psoriasis and vice versa. While psoriasis primarily manifests as a skin disorder, its association with liver diseases underscores the importance of holistic management and interdisciplinary collaboration in clinical practice.